Vascular Biogenics Ltd. - Ordinary Shares (VBLT): Price and Financial Metrics


Vascular Biogenics Ltd. - Ordinary Shares (VBLT)

Today's Latest Price: $1.47 USD

0.12 (8.89%)

Updated Dec 2 4:00pm

Add VBLT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

VBLT Stock Summary

  • Of note is the ratio of Vascular Biogenics Ltd's sales and general administrative expense to its total operating expenses; merely 9.6% of US stocks have a lower such ratio.
  • VBLT's price/sales ratio is 57.46; that's higher than the P/S ratio of 95.77% of US stocks.
  • In terms of volatility of its share price, VBLT is more volatile than just 6.09% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Vascular Biogenics Ltd, a group of peers worth examining would be GRTS, SYBX, MGNX, MTEM, and KALV.
  • VBLT's SEC filings can be seen here. And to visit Vascular Biogenics Ltd's official web site, go to www.vblrx.com.

VBLT Stock Price Chart Interactive Chart >

Price chart for VBLT

VBLT Price/Volume Stats

Current price $1.47 52-week high $1.64
Prev. close $1.35 52-week low $0.90
Day low $1.30 Volume 713,606
Day high $1.48 Avg. volume 389,237
50-day MA $1.19 Dividend yield N/A
200-day MA $1.25 Market Cap 61.64M

Vascular Biogenics Ltd. - Ordinary Shares (VBLT) Company Bio


Vascular Biogenics Limited is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases. The company was founded in 2000 and is based in Or Yehuda, Israel.


VBLT Latest News Stream


Event/Time News Detail
Loading, please wait...

VBLT Latest Social Stream


Loading social stream, please wait...

View Full VBLT Social Stream

Latest VBLT News From Around the Web

Below are the latest news stories about Vascular Biogenics Ltd that investors may wish to consider to help them evaluate VBLT as an investment opportunity.

VBL Therapeutics EPS in-line, misses on revenue

VBL Therapeutics (VBLT): Q2 GAAP EPS of -$0.14 in-line.Revenue of $0.16M (+14.3% Y/Y) misses by $0.01M.Shares -5.22% PM.Press Release...

Seeking Alpha | August 13, 2020

VBL Therapeutics cash consumption increases; shares slip 7%

VBL Therapeutics ([[VBLT]]) Q2 results:Revenues: $0.2M (+14.3%).Net loss: ($5.8M) (-23.4%); loss/share: ($0.14) (-7.7%).Cash used in operations: ($12.6M) (-137.7%).The investigator sponsored studies of VB-111 in GBM and colorectal cancer are headed for initiation.Yesterday, The independent Data Safety Monitoring Committee completed second interim analysis of OVAL Phase 3 study of VB-111 in...

Seeking Alpha | August 13, 2020

MORNING BID-Fog, stall ... rally

The views expressed are her own.) As U.S. coronavirus cases hit records and reopenings are dialled back, Federal Reserve officials admitted economic growth forecasts from the June policy meeting did not factor in the risk of a second wave. Fed Governor Lael Brainard summed it up as "a thick fog of uncertainty" and said "downside risks predominate." A similar message from the corporate world -- Delta Airlines CEO Ed Bastian said the industry was "at a stall right now."

Yahoo | July 15, 2020

Growth Investors: Industry Analysts Just Upgraded Their Vascular Biogenics Ltd. (NASDAQ:VBLT) Revenue Forecasts By 24%

Vascular Biogenics Ltd. (NASDAQ:VBLT) shareholders will have a reason to smile today, with the analysts making...

Yahoo | June 25, 2020

VBL Therapeutics Presents MOSPD2 Bi-Specific Antibody Activity and Potential Survival Benefit for Solid Tumors in Late Breaking Research Session of the AACR Virtual Annual Meeting

VBL Therapeutics (Nasdaq: VBLT) today presented a late-breaking study showing that its proprietary MOSPD2 bi-specific antibody candidates induced T-cell activation and significantly extended the survival of animals carrying established metastatic cervical and breast cancer (p=0.001; p=0.002). Data are presented today at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, being held June 22–24, 2020.

Yahoo | June 22, 2020

Read More 'VBLT' Stories Here

VBLT Price Returns

1-mo 26.72%
3-mo 26.72%
6-mo 13.95%
1-year 17.60%
3-year -78.54%
5-year -72.00%
YTD 22.50%
2019 23.71%
2018 -86.34%
2017 46.39%
2016 -7.79%
2015 -11.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8328 seconds.